EGFR and non-small cell lung carcinoma: BDTX-189, osimertinib, and DZD9008, as novel ERBB inhibitors, are now under evaluation in phase 1/2 clinical trial in patients with solid tumors and NSCLC with mutations or alternations in HER2 or EGFR, respectively (ClinicalTrials.gov identifier: NCT04209465, NCT03586453, NCT03974022).